On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. As legitimate compounding pathways narrow, independent analytical testing becomes the only reliable defense against substandard supply.

98% pure is the most common claim in the peptide industry. But what is the other 2%? A peptide impurity investigation.

Six major publications ran peptide safety stories in five days. We read all of them, traced their claims back to the data, and found a more complicated picture than any single headline captured.

Six major publications ran peptide safety stories in five days. We read all of them, traced their claims back to the data, and found a more complicated picture than any single headline captured.